DealForma Logo White
  • FEATURES
  • PRICING
  • ANALYSIS
  • SCHEDULE YOUR DEMO
  • SIGN IN
SCHEDULE A DEMO
SIGN IN
January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

by DealForma Analysts | Feb 10, 2022 | Deal of the Month

Deal of the Month January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases January 2022 Top Biopharma Deal Upfront Beam research partnership with Pfizer with a license option for up to three therapies for rare...
December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments

December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments

by DealForma Analysts | Jan 10, 2022 | Deal of the Month

Deal of the Month December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments December 2021 Top Biopharma Deal Upfront Foghorn partnership with Loxo (Eli Lilly) for selective BRM oncology therapies Announced: December...
November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

by DealForma Analysts | Dec 8, 2021 | Deal of the Month

Deal of the Month November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline November 2021 Top Biopharma Deal Upfront Owkin discovery and development deal with Sanofi for...
October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

by DealForma Analysts | Nov 5, 2021 | Deal of the Month

Deal of the Month October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies Top Biopharma Partnership by Upfront Cash and Equity October 2021 Xencor development and commercialization deal with Janssen for plamotamab and XmAb...
September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

by DealForma Analysts | Oct 7, 2021 | Deal of the Month

Deal of the Month September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy Top Biopharma Partnership by Upfront Cash and Equity September 2021 REGENXBIO development and commercialization deal with AbbVie for RGX-314...
August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors

August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors

by DealForma Analysts | Sep 8, 2021 | Deal of the Month

Deal of the Month August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity August 2021 RemeGen development and commercialization deal with Seagen for disitamab...
Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer

Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer

by DealForma Analysts | Aug 1, 2021 | Deal of the Month

Deal of the Month Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer Top Biopharma Partnership by Upfront Cash and Equity July 2021 Arvinas development and commercialization deal with Pfizer for ARV-471...
Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors

Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors

by DealForma Analysts | Jul 1, 2021 | Deal of the Month

Deal of the Month Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors Top Biopharma Partnership by Upfront Cash and Equity June 2021 iTeos development and commercialization deal with GSK for EOS-448 Announced: June 14, 2021...
Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer

Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer

by DealForma Analysts | Jun 5, 2021 | Deal of the Month

Deal of the Month Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer Top Biopharma Partnership by Upfront Cash and Equity May 2021 Agenus development and commercialization deal with BMS for AGEN-1777...
Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

by DealForma Analysts | Apr 30, 2021 | Deal of the Month

Deal of the Month Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia Top Biopharma Partnership by Upfront Cash and Equity April 2021 CRISPR Therapeutics amending its development and...
« Older Entries
Next Entries »

DealForma Blog

  • Analysis
  • Deal of the Month
  • Funding
  • M&A
  • Partnership Deals

Log In

Login with Okta
DealForma Logo Blue

DealForma is the biopharma database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Company

About Us

Analysis / Blog

Contact Us

Database

Features

Support

Pricing

Connect

  • Follow
  • Follow

Made in San Mateo, CA and around the world    [email protected]   (650) 353-9363

Terms    Privacy

Copyright © 2023 DealForma